Genmab Adr (GMAB)

概要ニュース株価時系列オプションチェーンなぜGMABが下落しているのか？ディスカッション予測株式分割

なぜGenmab Adr（GMAB）の株価が下がっていますか？

2026-01-16 の取引セッション中に、Genmab Adr (GMAB) 株の 5.23% 下落を確認しました。これは通常のボラティリティやさまざまな内部および外部要因に起因する可能性がありますが、当社では状況を積極的に監視しており、できるだけ早くタイムリーな最新情報を提供することに注意してください。

2023-10-18:

Genmab A/S Stock (GMAB) dropped by 7.96% from $31.92 to $29.38 in the trading on Wednesday October 18, 2023. The reasons why GMAB stock down today include:

Key drug Darzalex Q3 sales: Danish biotech reported that Darzalex, a multiple myeloma therapy the company markets with Johnson & Johnson (JNJ), generated $2.5B in net sales in Q3 2023, 2% less than what was expected by both companies.
Concerns about Epkinly launch: Epkinly, Genmab's newly FDA-approved lymphoma drug, is navigating a competitive landscape with peer Roche's Columvi, impacting its market reception and potential earnings.
Rating from analyst: Nordnet analyst Per Hansen flags Exane BNP Paribas' initiation of coverage with an 'underperform' rating due to Epkinly concerns, which is a headwind causing GMAB stock down today.

INCY

$100.07

1.00%

RVMD

$96.95

1.27%

BNTX

$113.75

2.59%

INSM

$156.87

0.60%

ONC

$340.38

2.75%

Genmab Adr (GMAB)

なぜGenmab Adr（GMAB）の株価が下がっていますか？

GMABに似た銘柄